Ignite Creation Date:
2024-05-05 @ 11:02 PM
Last Modification Date:
2024-10-26 @ 10:28 AM
Study NCT ID:
NCT01246908
Status:
COMPLETED
Last Update Posted:
2012-07-10
First Post:
2010-11-02
Brief Title:
Efficacy Safety and Tolerability of CX157 in Treatment Resistant Depression
Sponsor:
CeNeRx BioPharma Inc
Organization:
CeNeRx BioPharma Inc
Study Overview
Official Title:
A Randomized Double-Blind Placebo-Controlled Parallel-Group Assessment of the Efficacy Safety and Tolerability of CX157 Modified Release Tablet 125 mg Twice Per Day in Subjects With Treatment Resistant Depression
Status:
COMPLETED
Status Verified Date:
2012-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CX157-201
Brief Summary:
The purpose of this study is to determine if CX157 is effective and safe in patients with treatment of treatment resistant depression over six weeks of treatment
Detailed Description:
The primary objective of this study is to examine the efficacy of CX157 Modified Release Tablet 125 mg administered twice per day BID as compared to placebo in subjects with Treatment Resistant Depression TRD Secondary objectives are to evaluate the safety and tolerability of CX157 Modified Release Tablet 125 mg BID in TRD subjects and characterize steady-state pharmacokinetic profile and explore pharmacodynamic relationships
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None